RCAG
AZN icon

Rehmann Capital Advisory Group’s AstraZeneca AZN Stock Holding History

Rehmann Capital Advisory Group’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.38M Buy
7,001
+39
+0.6% +$7.52K 0.07% 193
2025
Q4 		$1.28M Buy
6,962
+1,297
+23% +$227K 0.07% 196
2025
Q3 		$869K Buy
5,665
+729
+15% +$110K 0.05% 256
2025
Q2 		$690K Sell
4,936
-709
-13% -$99.4K 0.04% 288
2025
Q1 		$830K Buy
5,645
+285
+5% +$41.2K 0.05% 253
2024
Q4 		$702K Buy
5,360
+346
+7% +$48.4K 0.04% 269
2024
Q3 		$788K Buy
5,014
+88
+2% +$14.2K 0.05% 249
2024
Q2 		$768K Buy
4,926
+797
+19% +$120K 0.06% 247
2024
Q1 		$560K Buy
4,129
+273
+7% +$36.1K 0.04% 297
2023
Q4 		$519K Buy
3,856
+1,245
+48% +$162K 0.04% 308
2023
Q3 		$354K Sell
2,611
-27
-1% -$3.69K 0.03% 365
2023
Q2 		$378K Sell
2,638
-127
-5% -$18.7K 0.03% 367
2023
Q1 		$384K Buy
2,765
+119
+4% +$16K 0.04% 359
2022
Q4 		$359K Buy
2,646
+21
+0.8% +$2.63K 0.04% 365
2022
Q3 		$288K Buy
2,625
+300
+13% +$38.1K 0.03% 391
2022
Q2 		$307K Buy
2,325
+426
+22% +$55.9K 0.03% 368
2022
Q1 		$252K Sell
1,899
-421
-18% -$50.5K 0.02% 445
2021
Q4 		$270K Sell
2,320
-152
-6% -$17.9K 0.03% 460
2021
Q3 		$297K Buy
+2,472
New +$288K 0.03% 440
2020
Q4 		– Sell
-2,228
Closed -$244K – 483
2020
Q3 		$244K Buy
2,228
+124
+6% +$13.8K 0.03% 364
2020
Q2 		$223K Buy
+2,104
New +$217K 0.03% 381
2019
Q3 		$150K Buy
1,687
+160
+10% +$13.9K 0.02% 365
2019
Q2 		$126K Sell
1,527
-42
-3% -$3.29K 0.02% 546
2019
Q1 		$127K Buy
1,569
+122
+8% +$9.62K 0.02% 526
2018
Q4 		$110K Buy
1,447
+168
+13% +$13.1K 0.02% 386
2018
Q3 		$101K Hold
1,279
– – 0.01% 585
2018
Q2 		$89.8K Sell
1,279
-273
-18% -$19.6K 0.01% 585
2018
Q1 		$109K Buy
+1,552
New +$108K 0.02% 520

Other funds holding AZN

IA
Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
VAM
Vanguard Asset Management London, Ec4n 8af $117B AUM

Rehmann Capital Advisory Group's AZN Position: Q1 2026 in Review

Rehmann Capital Advisory Group increased its AstraZeneca (AZN) stake by 0.56% in Q1 2026, buying an estimated $7.52K and bringing the position to 7,001 shares worth $1.38M. The position accounts for 0.07% of the portfolio, ranked #193.

Rehmann Capital Advisory Group first reported a position in AZN in Q1 2018 and has held it in 28 quarters since. 1,379 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

  • Rehmann Capital Advisory Group held 7,001 shares of AstraZeneca worth $1.38M as of Q1 2026.
  • Rehmann Capital Advisory Group bought 39 AstraZeneca shares in Q1 2026, an estimated $7.52K.
  • AstraZeneca made up 0.07% of Rehmann Capital Advisory Group's portfolio in Q1 2026, its #193 holding.
  • Rehmann Capital Advisory Group first reported a position in AstraZeneca in Q1 2018 and has held it in 28 quarters since.
  • 1,379 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on Rehmann Capital Advisory Group's 13F filing for Q1 2026, filed 15 May 2026.